Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432

作者：Aoki Masatoshi; Ueda Shugo; Nishikawa Hiroyoshi; Kitano Shigehisa; Hirayama Michiko; Ikeda Hiroaki; Toyoda Hideki; Tanaka Kyosuke; Kanai Michiyuki; Takabayashi Arimichi; Imai Hiroshi; Shiraishi Taizo; Sato Eiichi; Wada Hisashi; Nakayama Eiichi; Takei Yoshiyuki; Katayama Naoyuki; Shiku Hiroshi; Kageyama Shinichi^*

来源：Vaccine, 2009, 27(49): 6854-6861.

DOI：10.1016/j.vaccine.2009.09.018

• Antibody response
• NY-ESO-1
• HER2

Combination vaccines of the NY-ESC-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible.

• 出版日期2009-11-16